No connection

Features Terminal AI Assistant

Symbol search

/fundamentals

Enter to jump straight to the ticker page.

Search Results

Earnings Score 55 Bullish

Amgen’s subcutaneous Tepezza meets phase 3 trial endpoints

Apr 06, 2026 13:09 UTC

AMGN, IVV, ^RXI

Short term

Amgen’s subcutaneous Tepezza meets phase 3 trial endpoints.

Share this article

Article Stats

Impact

55

Sentiment

Bullish

Type

Earnings

Horizon

Short

Risk Level

Medium

Affected Symbols

Intelligence Terminal Fundamental Analysis Ask AI About This Advanced Chart More News

Intelligence Terminal Fundamental Analysis Ask AI About This Advanced Chart More News

Intelligence Terminal Fundamental Analysis Ask AI About This Advanced Chart More News

Analyze This News with AI

AI will analyze the impact on affected symbols and provide trading insights

Unlock Premium

Get AI-powered insights, advanced filtering, real-time alerts, and unlimited analysis.

Unlimited AI market analysis
Advanced news filtering
Real-time price alerts
AI trading assistant

View Plans Sign Up Free

Related Articles

Score 55 Bullish

Amgen posts positive late-stage results for subcutaneous Tepezza

Apr 06, 14:44

BlackRock files for Nasdaq-100 fund, expanding competition with Invesco

Apr 06, 14:25

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans